ImmunoCellular Therapeutics Ltd

ImmunoCellular Therapeutics is a biotechnology firm pioneering immune-based therapies to harness the body's defenses against cancer through advanced immunotherapy development. Founded in 2006, the company focuses on creating immune-based treatments for cancers. Its flagship product, ICT-107, is a dendritic cell (DC) immunotherapy designed to treat newly diagnosed glioblastoma multiforme (GBM), a highly aggressive brain cancer. This approach involves stimulating a patient's immune system to target tumor antigens, which are molecular signals used by the immune system to identify foreign bodies. In September 2015, ImmunoCellular Therapeutics secured a significant $19.90M grant investment from the California Institute for Regenerative Medicine. This funding showcased confidence in the potential of the company's immunotherapy technology. ImmunoCellular Therapeutics operates in the biotechnology and healthcare sectors, positioning itself at the intersection of innovative medical advancements and addressing critical oncological needs. Their groundbreaking approach to immunotherapy development holds promise for revolutionizing cancer treatment and making significant strides in improving patient outcomes.